Radiopharmaceutical provider Syncor has announced that the University of Kentucky Chandler Medical Center in Lexington, KY, has become the first U.S. institution to use the vendor’s PharmaSeed Iodine-125 brachytherapy seeds for the treatment of localized prostate cancer. The first I-125 brachytherapy procedures outside the U.S. were performed in March in Thailand, according to the Woodland Hills, CA-based firm.
By AuntMinnie.com staff writersJuly 26, 2000
Related Reading
Syncor brachytherapy seeds cleared by FDA, January 12, 2000.
Copyright © 2000 AuntMinnie.com
Copyright © 2000 AuntMinnie.com